Introduction
We noted earlier [1] that 1978 was the turning point in current public perception of traditional medicine (TM) following the famous WHO declaration at Alma-Ata. That declaration ushered in a positive attitude that paved the way for the present global popularity of TM, especially herbal medicine. We noted earlier also [2, 3] that whereas herbal remedies are called dietary supplements in the US, thereby shifting emphasis away from their medicinal attributes, the Dietary Supplement Health Education Act of 1994 [4] , which occasioned the shift, actually helped to promote herbal medicine in the US, albeit indirectly, through the innovative provision it made for user information [5, 6] . A similar situation obtained in Europe, where the net effect of the laws and rules passed in 2004 on herbal remedies had been to promote their production and use [7, 8] . In terms of trade and economics of herbal drugs, the following fact is notable: Although, Asia contributed only US$ 7.3 billion to herbal world trade in 1999 [9] , by 2005, a mere 6 years, China's contribution alone rose to US$ 14 billion [10] . This stupendous growth was due to policies and programmes that favoured herbal medicine -the cornerstone of Traditional Chinese Medicine (TCM). Similar situations as in China held sway in Japan, South Korea and the Indian sub-continent, where government policies also favoured herbal medicine. However, in many developing countries like Nigeria, a totally different picture obtained, not because policies were expressly against herbal medicine, but in these countries there had been a lingering absence of proper policies and laws supportive of traditional remedies. Another key fact on the political economy of herbal drugs is that: Although, about 80% of people in developing countries depended on herbs, these countries contributed only 7.2% to herbal drug trade in 1999. By contrast, the developed nations, where people relied less on herbs, contributed 55.2%. Asia, less Japan and South Korea, contributed 37.6%. Equally interesting is the comparison of Brazil with Nigeria. Both are rich in medicinal plants and have high populations that depend substantially on herbs. But, while herbs contributed an unknown amount to the Nigerian economy in 2007, in Brazil it contributed US$ 160 million. By contrast, Nigeria's entire federal budget for health in 2007 was a mere US$ 800 million [2] . These findings earlier led us [11, 12] to conclude that developing countries need strategies that will enhance the regulation of herbal drugs and promote their trade. The present article is an attempt to enunciate one of such strategies. It is particularly of note that the superior performance of Brazil in comparison with Nigeria indicates that with proper policies and strategies, herbs can indeed contribute substantially to any economy. application throughout the organization; determine the sequence of the processes and their interactions; determine the criteria and methods for operating and controlling the processes; determine and ensure the availability needed resources and supporting information; check, measure and analyze the processes, where applicable; and implement actions to achieve planned results and continual improvement of the processes. The organization shall manage the processes above in accordance with ISO 9001:2008 requirements. It shall also define the type and extent of control to be applied to any outsourced process that can affect product conformity to requirements. ISO 9001:2008 specifically notes as follows:
1 Management responsibility corresponds to clause 5 of ISO 9001; while Resource management, Product realization and Measurement/ analysis/ improvement correspond to clauses 6, 7 and 8 respectively.
1.
Processes needed for the QMS include the processes for management activities (clause 5), provision of resources (clause 6), product realization (clause 7), and measurement, analysis, and improvement (clause 8).
2. An outsourced process is a process the organization needs for its QMS, and which the organization chooses to have performed by an external party.
3.
Ensuring control over outsourced processes does not absolve the organization of the responsibility to conform to customer and legal requirements.
The type and extent of control applied to an outsourced process can be influenced by factors such as: the potential impact of the outsourced process on the organization's capability to provide product that conforms to requirements; the degree to which the control over the process is shared; and the capability of the organization in achieving the necessary control via the application of sub-clause 7.4 (Purchasing). Philosophically, ISO 9001:2008 is formulated on the basis of management by objectives (MBO) and draws upon eight quality management principles. Ideally therefore, quality assurance covers activities in research, development, production and documentation. It embraces the rule: "do it right the first time". It involves regulating the quality of raw materials, the state of production line and works-in-progress, the product and related management processes. One of the most widely used paradigms for quality assurance management (QAM) is the "Shewhart cycle", also called "PDCA approach", meaning, "Plan-Do-Check-Act" [13, 14] . The foregoing is illustrated in Figure 1 using NIPRD QMS processes as an example.
The eight quality management principles that underlie ISO 9001:2008
Like other ISO standards (Example: ISO 9004 -Managing for Sustained Success), ISO 9001:2008 is based on 8 quality management principles that are aligned with the philosophy and objectives of most quality award programmes in the world's most industrialized nations. The 8 principles are associated with the following themes:
1. Customer focus.
Leadership.
3. Involvement of people.
4.
Process approach to management.
5.
System approach to management.
6. Continual improvement.
7.
Factual approach to decision making.
8.
Mutually beneficial supplier relationships.
Key terminologies of ISO 9001:2008

Process approach to management
A process is an activity or operation that receives inputs and converts them to outputs. Practically all activities or operations involved in generating a product or providing a service are processes. For an organization to function, it must define and manage several inter-linked processes. Most often, the output of one process becomes the input into the next process.
The systematic identification and control of the various processes employed within an organization, and the interactions between such processes, is termed "process approach" to management. Thus process approach to management is a way of obtaining a desired result, by controlling activities and related resources as a process. Process approach is a key element of all ISO 9000 standards, including ISO 9001:2008.
System approach to management
System approach to management is based on the premise that the efficiency and effectiveness with which an organization achieves its quality objectives are contributed and enhanced by identifying, understanding and managing all the interrelated processes within the organization as a system
Quality policy
Quality policy is a formal statement from the management of an organization that is linked to the nature of its business and its plans to meet the needs of its customers/ stakeholders. The policy is designed to be understood and followed at all levels and by all staff.
Quality objective
Quality objective is the factual or tangible basis upon which quality policy and plans for implementing the quality programmes of an organization are built. Quality objective should be SMART (ie: specific, measurable, achievable, realistic and time-bound). Each staff of the organization is expected to work towards measurable objectives.
Decision
Decision simply means the selection of one or more options from a multitude of options in tackling a given organizational task. As far as the QMS is concerned, an organization should make SMART decisions based on recorded data. An example of a SMART decision is: The QMS must be audited and evaluated regularly for conformance and effectiveness, so as to assure quality and continual improvement.
Traceability
Traceability is concerned with and refers to the fact that typically, recorded data are meant to show how and where raw materials and products were processed, in order to allow products and problems to be traced to their sources.
Product realization
Product realization refers to the scenario in which, when developing a new product, an organization plans the stages of development, with appropriate testing at each stage. The organization tests and documents whether the product meets design requirements, legal requirements, and user or customer needs.
Quality plan
Quality plan refers to a document specifying the QMS processes (including the product realization processes), and the resources to be applied to a specific product or project.
Monitoring and measurement
Monitoring and measurement refer to the scenario in which an organization must regularly review its performance through meetings and internal audits, and determine whether the QMS is working and what improvements can be made. The organization must have a documented procedure for internal audits and a procedure for dealing with past problems and potential problems. It must keep records of these activities and the resulting decisions, and monitor their effectiveness. It must have documented procedures for dealing with actual and potential nonconformances (problems involving suppliers, customers, or internal problems).
Continual improvement
Continual Improvement refers to the scenario in which an organization 1) makes sure no customer uses a bad product, 2) determines what to do with a bad product, 3) deals with the root cause of problems, and 4) keeps records to use as a tool to improve the QMS.
Customer requirements
Customer requirements refer to the attributes that the buyer of a product (or user of a service) wants. The core business of an organization is to determine customer requirements and to meet them, in accordance with sub-clause 5.2 (Customer focus).
Drug Regulatory Agencies (DRAs)
Drug regulatory agencies (DRAs) are organizations set up by the State on behalf of the general public with a Mandate to regulate drugs and related products and services. The Mandate of some DRAs may include production and distribution of certain goods like vaccines and orphan drugs. Either the State or the general public can be regarded as customer, stakeholder or shareholder. DRAs like all other organizations must have a system for communi-cating with customers or stakeholders about product information, inquiries, contracts, orders, feedback, and complaints. All DRAs are "service providers" but some produce and even distribute certain specific items, as mentioned above. Nigeria's National Agency for Food and Drug Administration and Control (NAFDAC) is a national DRA, while the European Medicines Evaluation Agency is a regional DRA.
Mandate
Mandate is a piece of legislation or instruction from a constituted authority to another constituted authority or body to carry out a named task. DRAs are mandated by the State to regulate drugs and health related products.
The new industrial revolution and the aim of this chapter
It is well established that the high state of development in the chemical/ pharmaceutical industrial sector in the US, Japan, South Korea, Britain, Germany and other European countries owes much to the powerful synergy between regulatory legislations, industrial standards and a focused political will. It is also manifest that the rapid, all-round industrial revolution in China in the past decade or so owes much to China's embrace of ISO standards, especially ISO 9001, as shown in Table 1 after a recent [15] . Most or all countries have a national or regional agency that regulates the production, distribution and use of drug products. The process of regulation commences with the registration of the producer, the product, the distributor and in some cases the user. In some countries drugs, foods and dietary supplements are regulated by the same body (eg: Nigeria's NAF-DAC and US-FDA). The EU's EMEA however regulates only drug products. States or regions need to have DRAs in order to ensure order in the production, distribution and use of drugs. Without DRAs utter chaos and pandemonium will result in production (eg: manufacturers will do as they please without a uniform control), distribution (distributors and suppliers will do as they choose without a uniform order) and use (prescribers and users will do as they think without a uniform regime), which would allow incidences of counterfeit and expired drugs in drug distribution chain, drug abuse and emergence of drug resistant disorders, especially infective conditions like malaria and TB.
Comparative analysis of Nigeria's and EU's requirements for herbal drug regulation
A careful scrutiny of the requirements for registering and regulating herbal drugs in Europe and in Nigeria reveals their basic similarity, as shown in Table 2 . Refer to GMP requirements for production.
These include: production must be in a GMP compliant, product must be produced with validated formula and method, there must be a product specification, stability studies must be carried out in the container proposed for marketing for purposes storage/ shelflife, and dossiers must be provided for starting materials and finished product. Table 3 for extra requirements).
*The Table was drawn based on data gathered from references including Goldman [5] ; De Smet [7, 8] ; Ann Godsell Regulatory [16] ; and various NAFDAC leaflets, including Akunyili [17] . Note that the requirements for registration in Nigeria are not necessarily less tasking, but their lack of explicitness can be a booby trap and a leeway for non-transparency. The necessity for explicitness and transparency is very important because some years ago the Director General of China's drug regulatory agency was sentenced to death for alleged corrupt practice [18] . In 2000 the entire Management of NAFDAC was sacked in similar grey circumstances. But, while the EMEA approach is technically more explicit, though not necessarily more exerting than NAFDAC's, the latter is administratively much more cumbersome, and therefore more liable to inefficiency and abuse. Table 3 shows the extra bureaucratic demands of NAFDAC. We stated earlier that, although, 80% of people in developing countries like Nigeria depended on herbs, these countries contributed only 7.2% to herbal drug trade in 1999.
By contrast, the developed nations, where people relied less on herbs, contributed 55.2%.
This scenario is explained by the fact herbal drugs are better regulated in developed regions like the China, India, Japan and South East Asia, the EU and North America [2] . [15, 19] ; b) studies indicate significant financial benefits for organizations certified to ISO 9001 [19, 20] ; and c) similar superior operational performance of ISO certified firms has been severally confirmed [21] [22] [23] [24] . As just noted, ISO 9001:2008 is an update of ISO 9001:2000, and we have selected it for this study by reason of its popularity and versatility, and because it is a process-based QMS that addresses systemic change affecting whole organizations like a national or regional drug DRA, like Nigeria's National Agency for Food and drug Administration and Control (NAFDAC), the US Food and Drug Administration (US-FDA) and the European Medicines Evaluation Agency (EMEA). Table 2 . It is well known that herbal drugs are better regulated in the developed than in developing countries. The term "product" may also mean "service". "Legal requirements" means "statutory and regulatory requirements". Most DRAs are service providers only, while others may produce and distribute certain specialized health products.
S/No Extra requirement Remark
*The Table is to be studied side by side with the contents of ISO 9001:2008 and Table 2 , which is on regulatory requirements of DRAs. 
Quality manual -this should
include the scope of the QMS, SOPs and a description of the QMS processes.
Control of documents -the documents required
by the QMS must be established and controlled. This means that SOPs are to be established to define the controls needed.
Control of records -records are a
special type of documents and must be established and controlled. Here too, SOPs are to be established to define the controls needed.
Note:1)
A document is a piece of written, printed, or electronic matter that provides information or evidence.
It may or may exist Clause 4.1 implies that the DRA must identify, manage and document the processes that make up its QMS -ie: the DRA must address the so called "Six Quality Procedures" and generate relevant documents, including: 1) quality manual, 2) quality policy, 3) quality objective, 4) process flowchart, and 5) work instructions. The DRA can achieve this by using a management strategy called "process approach", which means that it must manage: 1) the processes that make up its organization, 2) the interaction between these processes, and 3) the inputs and outputs that glue these processes together. The quality manual should: 1) describe how the QMS processes interact; 2) define the scope of the QMS (it should explain any reductions in the scope of the QMS and justify all exclusions/ reductions); and 3) document all procedures in the QMS or refer to them. It is most crucial that the DRA prepares, establishes and maintains a quality manual.
The DRA must establish SOPs to define the controls needed: 1) to approve, review, update and re-approve documents prior to use; 2) to ensure that changes, current status, relevant versions of documents are identified; and 3) to prevent the unintended use of obsolete documents. The DRA must establish records to provide: 1) evidence that operations conform to QMS requirements; and 2) evidence that operations of the QMS are effective. Records must be ensured to be legible, readily identifiable and retrievable. Table 2 , which is on regulatory requirements of DRAs. Table 2 , which is on regulatory requirements of DRAs. In this latter disaster a hitherto popular brand of paediatric mixture ("My Pikin") was found to contain ethylene glycol that had been purchased from an unregulated source. It is important to note that whereas the glycol implicated in the Lantang disaster was purchased from pharmaceutically regulated source, the glycol in the case of the Lagos disaster was purchased from a company that dealt in industrial chemicals associated with automobiles and cooling systems. The occurrence of this kind of disaster within less than two decades is matter of concern that calls for a more efficient programme for regulating drugs and industrial chemicals in developing countries. The US-FDA after whose image and likeness NAFDAC was created is known for efficiency mostly because it is supported by proper laws and strong institutions. Better laws and stronger institutions, including DRAs, are required to avoid or minimize this kind of disaster as seen in Nigeria. It seems instructive to mention the "Tylenol case" in the US, and how that case led to a new legislation. Between late September and early October 1982, seven persons in Chicago died after taking capsules of Tylenol (a brand of paracetamol), to which cyanide crystals had been added. The crystals had apparently been introduced into the capsules by someone who had removed bottles of Tylenol from several drugstores and then replaced them on the shelves. It took an intensive investigation by a team of over 100 agents, including FDA staff, to discover the mischief, which led to a 1982-legislation that required all over-the-counter drugs and medicines sold in the county (and later elsewhere in the US and beyond) carry manufacturers' seals which broken would be obvious. The rapid conclusion of the investigation led by the Illinois Attorney General himself (Tyrone C. Fahner) and the dispatch with which the new law was issued collectively testify to the inner workings of strong institutions -which developing nations lack. 
Infrastructure
Like any other public outfit the DRA must determine, provide, and maintain infrastructure like buildings, workspace and associated utilities, and essential support services.
Work Environment
"Work environment" implies conditions under which work is performed, and includes physical aspects like weather and noise pollution.
The DRA must determine and provide the resources needed: 1) to implement, maintain and continually improve the effectiveness of its QMS; and 2) to enhance the fulfilment of its Mandate.
By virtue of its role as a highly specialized agency, the DRA must ensure that all staff irrespective of department whose work can impact DRA's Mandate are competent based on appropriate education, skills, experience and abide by their professional ethics.
This implies that the DRA must: 1) determine the competency of staff; 2) provide training as needed; 3) evaluate the effectiveness of the actions taken on training and skills acquisition ; 4) inform staff of their relevance within the QMS; 5) ensure staff know their contributions to achieving quality objectives; and 6) maintain staff records of education, training, skill, and experience in accordance with clause 4.2.4.
The DRA must, of course, provide appropriate work environment for all staff whose work impacts the DRA's Mandate.
*The Table is to be studied side by side with contents of ISO 9001:2008 and Table 2 , which is on regulatory requirements of DRAs. 
The making of stronger DRAs and the need for clearer demarcation of responsibilities
In most countries where DRAs are not a department of the Ministry of Health, they exist as a parastatal or as a special department within the Ministry (as in Japan), with conditions of service being slightly more favourable than in the rest of the Ministry. The idea is to give special incentives to the staff on account of hazards perceived to be peculiar to the job. In Nigeria, NAFDAC is well housed both at the federal and state levels and the staff earn about the same remuneration as the universities and research institutes. In most countries the DRAs have well equipped offices and laboratories, and those DRAs that produce and distribute goods are equipped with the necessary plant and storage facilities.
The inevitability of confusion in the absence of regulatory standardization
In Nigeria, NAFDAC previously handled certain aspects of manufacture/ distribution of vaccines until certain developments (or rather controversies over quality/ effectiveness of polio vaccines during the late 1990s/ early 2000s) led, first to the creation of a National Programme on Immunization (NPI); and latter to the transfer of the same functions from NPI back to the Federal Ministry of Health. It is obvious from the foregoing that institutions like NAFDAC and NPI would have performed better had they been certified. It seems also that one of the keys to ending the cycle of poverty and underdevelopment in some countries is to ensure that elite institutions like the DRAs are certified to appropriate ISO standards. Certifications of agencies like the Health Insurance Scheme and the Pension Commission will definitely reduce perceive current levels of corruption in such institution.
Clause Title and subtitles, with remark
Salient points/ directing principles / application to DRAs The customers/ stakeholders of a typical DRA are the general public, manufacturers, suppliers and the government. DRAs that engage in production and distribution must determine customer requirements, which invariably include specified and unspecified but desirable attributes. Such DRAs must also determine the legal requirements applicable to the product. Other desirable requirements, including post-delivery activities like maintenance services, may be considered. DRAs that produce or distribute would normally review the product requirements before committing to supply in order to: 1) ensure that product requirements are defined; 2) resolve any requirements differing from those previously expressed; and 3) ensure its ability to meet the requirements. In the same vein when a DRA plans a regulatory strategy or legislation the plan should be graduated and made reasonable to its purpose and scope and with reference to the operating socioeconomic environment. The DRA must maintain the results of reviews, and any subsequent follow-up actions in accordance with 4.2.4. When the requirements are not documented, they must be confirmed before acceptance. But if product requirements are changed, the DRA must ensure relevant documents are amended and relevant personnel are made aware of the changed requirements.
NOTE: In some situations a formal review is impractical for each order. In such cases reviews can cover relevant product information such as catalogues or adverts.
*The Table is to be studied side by side with contents of ISO 9001:2008 and Table 2 , which is on the regulatory requirements of DRAs. 
Design/ Development Planning
DRAs that produce or distribute must plan and control product design/ development. They must determine 1) the stages of design/development; 2) appropriate testing, review and validation for each stage; and 3) responsibility/authority for design/ development.
Design /Development Inputs
In designing/ developing a physical good or a service, the DRA must determine the needed inputs and keep records as per 4.2.4.
The inputs must include: 1) functional and performance requirements; 2) applicable legal requirements; 3) applicable information derived from similar designs; and 4) requirements essential for design and development.
Design/ Development Outputs
Where applicable, DRAs must Validation activities are performed in accordance with 7.3.1 to confirm that the resulting product is capable of meeting the requirements for its specified application or intended use.
Control of Des./ Dev Changes
For either physical goods or policy, DRAs must 1) identify design and development changes and maintain records as per 4.2.4; 2) review, verify, validate and approve changes before implementation; 3) evaluate the changes in terms of their effect on constituent parts (raw material) and products (or policies) already delivered (or implemented).
The same principle followed in planning a physical product is followed in planning a service. The interfaces between the different groups involved must be managed to ensure effective communication/ clear assignment of responsibility. Design and development review, verification and validation have distinct purposes. They can be conducted and recorded separately or in any combination, as the DRA deems suitable for the product or the type of service.
A DRA would review the selected inputs for adequacy and resolve any incomplete, ambiguous, or conflicting requirements. Examples of application inputs include: (1 applicable information derived from similar designs; and (2 requirements essential for design and development. If a DRA is designing a policy to curb drug abuse in a particular locality, useful inputs for the design would include statistics like 1) the age, gender and occupation of abusers; 2) the type of drugs abused; and 3) the success rate of similar policies elsewhere. NOTE: Information for production and service can include details for product preservation.
A DRA must perform systematic reviews of design and development at suitable stages in accordance with planned arrangements (7. *The Table is to be studied side by side with contents of ISO 9001:2008 and Table 2 , which is on the regulatory requirements of DRAs. 
Some causes and signs of a malfunctioning DRA
Once the staff recruitment system can be skewed to favour persons, a serious non-compliance exists. Once the purchase processes can be demonstrated to have vested interest, a serious flaw exists in the QMS. Once there is a convincing evidence of maladministration, arbitrary treatment of personnel or executive high handed, a serious condition against performance exists.
Clause Title and subtitles, with remarks Salient points/ directing principles/ application to DRAs 
Validation of Processes for
Production and Service Provision
Identification and Traceability
Customer Property
Whether a DRA produces/ distributes it will have cause to purchase various items of commerce hence QMS requirements for purchases are required. Like other organizations a DRA would require and ensure the adequacy of the specifications of items to be purchased before communicating the purchasing information to the supplier. Typically a DRA would establish and implement inspection or other necessary activities for ensuring that purchased goods meet the specified purchase requirements. If a DRA or its customers/ stakeholders propose to verify a good or service at the supplier's location, the intended verification arrangements/ method must be stated in the purchasing information.
It is typically pertinent that a DRA 1) validates any production or service provision that 2. Calibrate the equipment to national or international standards (or record other appropriate basis).
3. Adjust or re-adjust as necessary.
4. Identify the measuring equipment in order to determine its calibration status 5. Safeguard equipment from improper adjustments.
6. Protect equipment from damage and deterioration *The Table is to be studied side by side with contents of ISO 9001:2008 and Table 2 , which is on the regulatory requirements of DRAs. 
General
A producing/ distributing DRA would plan and implement the monitoring, measurement, analysis, and improvement processes it needs to: 1) demonstrate conformity to product requirements; 2) ensure conformity of the QMS to planned arrangements; and 3) continually improve the effectiveness of the QMS.
Non-producing/ distributing DRAs must have the ability to ensure that manufacturers/ distributors comply.
Monitoring and measurement
Customer Satisfaction
DRAs must routinely: 1) monitor information on customer/ stakeholder perception as to whether it is meeting its Mandate; and 2) define the methods for obtaining and using that information.
Internal Audit
Given the overwhelming importance of measurement, analysis and improvement to the To institute thoroughness and effectiveness, producing/ distributing DRAs must:
1. Maintain records of the audits and their results.
2. Ensure control of the audited areas.
3. Take actions without undue delay to eliminate detected nonconformities and their causes.
4. Verify through follow-up actions. Table 2 , which is on the regulatory requirements of DRAs. 
Remediation of a malfunctioning DRA
A national or regional DRA is a critical factor in socioeconomic development and wellbeing in at least two ways: i) by "guaranteeing the health of the nation" (as trumpeted in NAF-DAC's adverts); and by supporting the emergence of responsible manufacturers of regulated products. It is well known that the US-FDA more than any US organization has made the US the world leader in manufacture of health products. The prominence of India and China in world drug trade owes much to the vibrancy and relative efficiency of their DRAs. There is therefore a critical need for DRAs to be vibrant and responsible. The gravity with which China views the role of her DRA can be gauged by the death sentence passed on the Director General in 2007 for accepting a bribe [15] .
Clause Title and subtitles, with remarks Salient points/ directing principles/ application to DRAs 2) Confirm through these methods the continuing ability of each process to satisfy its intended purpose.
3) When the planned results are not achieved, take correction and corrective action, as appropriate.
Monitoring and
Measurement of Product
Producing/ distributing DRAs need to 1) apply suitable methods for monitoring and measuring QMS processes; and 2) confirm through these methods the continuing ability of each process to satisfy its intended purpose.
NOTE: When determining "suitable" methods, consideration is given to the type and extent of monitoring or measurement for each process in relation to its impact on product conformity and on the effectiveness of the QMS.
To better fulfil their Mandate producing/ distributing DRAs must 1) monitor and measure product characteristics so as to verify if product requirements are being met; 2) carry out the monitoring and measurements at the appropriate stages of product realization in accordance with planned arrangements; and 3) maintain evidence of conformity with the acceptance criteria.
Clause Title and subtitles, with remarks
Salient points/ directing principles/ application to DRAs 1) Monitor and measure product characteristics to verify if product requirements are being met.
2) Carry out the monitoring and measuring at the appropriate stages of product realization in accordance with planned arrangements (see 7.1).
3) Maintain evidence of conformity with the acceptance criteria.
4) Record the person responsible for authorizing release of product for delivery to the customer.
Control of nonconforming product
DRAs must: 1) Ensure any nonconforming product is identified and controlled to prevent its unintended use or delivery.
2) Establish a documented procedure to define the controls and the related responsibilities/authorities for dealing with nonconforming product.
DRAs must maintain records of the nature of the nonconformity, and any subsequent actions, (including any concessions). When the nonconformity is corrected, DRAs must re-verify it to prove or show evidence of conformity.
It is again stressed that non-producing/ distributing DRAs must have the ability to ensure that manufacturers/ distributors comply.
DRAs must ensure that product release and service delivery cannot proceed until all planned arrangements (see 7.1) have been satisfactorily completed, unless otherwise approved by a relevant authority, and where applicable, the customer.
Where applicable, DRAs must deal with the nonconforming product by one or more of the following ways:
1. Take action to eliminate the detected nonconformity.
2. Authorize its use, release, or acceptance by concession.
3. Take action to preclude its original intended use or application.
4. Take action appropriate to the effects, or potential effects, of the nonconformity when nonconforming product is detected after delivery or use has started
To better fulfil their Mandate, DRAs must: 1) Ensure that any nonconforming product is identified and controlled to prevent its unintended use or delivery. 2) Establish a documented procedure to define the controls and related responsibilities and authorities for dealing with nonconforming product.
*The Table is to be studied side by side with contents of ISO 9001:2008 and Table 2 , which is on the regulatory requirements of DRAs. Although a DRA may not possess certain facilities for measurements and monitoring, it should possess the ability or the means necessary to ensure that manufacturers/ distributors possess and use them in accordance with approved QMS guidelines. In Nigeria, the entire NAFDAC Management was sacked on alleged acts of corruption in 2000. It seems to us that the following are essential for a DRA to perform optimally:
The laws creating/ amending a DRA should be well articulated as is the case with the US-FDA.
2.
DRAs should be so well funded as not to rely on a plethora of frivolous fees as with NAF-DAC.
3.
Staffing of DRAs must be transparent -competence and integrity must be the decisive criteria.
4.
DRAs should be audited frequently, at least yearly or twice yearly.
5.
DRAs should have a Board of Governors to whom the Management reports. 
Corrective Action
The standard practice for organizations is that:
1. Wherever a nonconformity or breach is detected, corrective action must be taken to eliminate the cause of the nonconformity and to prevent its recurrence.
2. Wherever corrective action is taken by an organization, such action must be such as is appropriate to the effects of the problem caused by the nonconformity or breach.
Preventive Action
Organizations must:
1. Determine in advance the action that needs to be taken to eliminate the causes of potential nonconformity, in order to prevent its occurrence.
2. Ensure that preventive actions are appropriate to the anticipated effects of the potential problem.
DRAs should as a matter of practice:
*The Table is to be studied side by side with contents of ISO 9001:2008 and Table 2 , which is on the regulatory requirements of DRAs. It must be stressed once again that if DRAs are to persuade manufacturers/ distributors to comply with the provisions of this and other clauses of ISO 9001:2008 industrial standard, they too must be conversant with and adept in them. 
Further remarks on clauses 7 and 8 of ISO 9001:2008
Although the principles of clauses 7 and 8 apply to all organizations, they are strictly speaking, the deeds and stuff intended for high profile institutions with elaborate concern and facilities for design and R&D, and with tall entrepreneurial ambition. Such organizations include the most successful pharmaceutical and biotechnology companies of the US, Europe, Japan and India; NASA, aircraft manufacturers, international airlines and 5-star hospitality concerns. However, in as much as DRAs must regulate the work and product of advanced pharmaceutical manufacturers, the onus is upon the DRAs themselves to be conversant with the entire provisions of these clauses and be as intellectually equipped as the manufacturer. This explains why it is often desirable that regulators have a stint in both academia and industry. In many countries, especially the US and India, top rate biomedical facilities/ institutions and personnel are to be found in the following four circles: i) the DRAs (eg: US-FDA); ii) health research institutions (eg: NIH); iii) the universities/ R&D institutions patronized by the DRAs; and iv) big transnational drug manufacturers (eg: Pfizer). We once again refer to the Nigeria polio vaccine controversy of the late 1990s/ early 2000s mentioned earlier, and ask the following question: When a DRA produces or distributes product as is the case in many developing economies, who regulates the DRA? Can subsequent revisions of ISO 9001or some other ISO standard provide an answer?
Conclusions
It is evident from the foregoing that all the eight clauses of ISO 9001:2008 apply to the Mandate of DRAs. However, most of what appears in clauses 7 and 8, the lengthiest of the clauses, relates more pertinently to high stake pharmaceutical manufacturers that have elaborate R&D than they do to the average DRA, which nevertheless should be thoroughly acquainted with the clauses. Some DRAs like the US-FDA and EMEA that have advance laboratories or access to such or that heavily fund R&D must be guided by the rigorous provisions of clauses 7 and 8. Needless to say, those DRAs that produce/ distribute products must be similarly guided to the extent of their relevance to the scope and size of their operations. The US-FDA, Japan's Ministry of Health and Social Services and EMEA are certified to appropriate performance standards and are known for their efficiency. By contrast NAFDAC and other developing national DRAs are not similarly certified and are less well known for efficiency, considering the rampancy of counterfeit drugs and other ills in their drug delivery systems. The DRAs of China, India and Southeast Asian countries compare quite well in many aspects with those of Europe, Canada and the US, and are by far more efficient than those of many African and South American countries. From the foregoing, and in view of the historical and international dimensions of phytotherapy, especially its galloping global patronage in recent times [1, 2, 11, 12] , it is necessary that there to be a minimum global standard to which DRAs should be certified. We propose ISO 9001 because of its global popularity, applicability and suitability. The standard provides the general climate for DRAs to efficiently discharge their Mandate. We project that a carefully planned application of ISO 9001 to herbal drug regulation will improve the production, distribution and usage of herbal drugs.
It will also boost the economy of developing economies that rely to a large extent on herbal drugs. But since the DRAs of many developing economies produce/ distribute certain products, there is a need for subsequent revisions of ISO 9001 to take cognisance of the question of who regulates the regulator that produces/ distributes? In the meantime we recommend that the Minister/ Secretary of Health and/ or the Parliamentary Committees of Health take note of this significant lacuna.
